Suzuki C.,Kouseiren Obihiro Hospital |
Hiura K.,Kouseiren Obihiro Hospital |
Sato H.,Kouseiren Obihiro Hospital |
Komori H.,Kouseiren Obihiro Hospital |
Yamamoto M.,Kouseiren Obihiro Hospital
Japanese Journal of Cancer and Chemotherapy | Year: 2011
Nausea and vomiting are major adverse reactions in cancer chemotherapy, and affect quality of life (QOL). We performed a retrospective study that examined the efficacy of aprepitant and palonosetron for chemotherapy-induced nausea and vomiting (CINV) on patients taking cisplatin doublets for lung cancer. The study subjects were 73 patients. A 5-HT 3 group received old-generation 5-HT 3 receptor antagonists and dexamethasone for preventive treatment (32 patients). An A group received old-generation 5-HT 3 receptor antagonists, aprepitant and dexamethasone (22 patients). An A+P group received palonosetron, aprepitant and dexamethasone (19 patients). On acute emesis (occurring within 24 hours after chemotherapy), there was no significant difference in the complete suppression rate of nausea and vomiting among the three groups. However, on delayed onset emesis (occurring between 24 to 120 hours), the complete suppression rate of nausea was significantly higher in the A+P group (57.9%) than in the 5-HT 3 group (16.7%) and A group (23.8%). Significantly better efficacy was seen in the 5-HT 3 group and A group in the complete suppression rate of vomiting, and in the need of rescue medication rates on delayed-onset emesis. The cost of antiemesis was 19, 735 yen for the 5-HT 3 group, 32, 252 yen for the A group and 15, 557 yen for the A+P group. In conclusion, it was suggested that concurrent administration of palonosetron, aprepitant and dexamethasone for CINV on cisplatin doublet in lung cancer is a clinically useful treatment that might reduce the economic burden on patients.